Risk of stroke in SLE: a systematic review and meta-analysis.

Lupus Sci MedSep 15, 2026 (epub)
Clinical ResearchRheumatologyNeurology

Jingya Zhang, Weiman Shi, Yaling Xu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the risk of stroke in patients with systemic lupus erythematosus (SLE) using data from 25 cohort studies involving 5,220,837 individuals. The analysis found a significantly increased risk of stroke in SLE patients, with a pooled risk ratio of 2.60 (95% CI 2.21 to 3.05, p<0.001).

Key findings

  • Pooled risk ratio for stroke in SLE patients was 2.60 (95% CI 2.21 to 3.05).
  • Composite stroke risk increased with a risk ratio of 2.83 (95% CI 2.25 to 3.57).
  • Ischaemic stroke risk was elevated with a risk ratio of 2.34 (95% CI 1.75 to 3.12).
  • Haemorrhagic stroke risk also increased, with a risk ratio of 2.66 (95% CI 1.57 to 4.49).

Why it matters

Understanding the increased risk of stroke in patients with SLE is crucial for clinicians, as it highlights the need for vigilant monitoring and potential preventive strategies in this population.

Source

PubMed · PMID 42744409

Published in Lupus Sci Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Rheumatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.